# Takeda Launches Narcolepsy Drug ORZEYFUL in Japan and China

- URL: https://stocks.freetheai.org/news/takeda-launches-narcolepsy-drug-orzeyful-in-japan-and-china-3c8e6f
- Published: 2026-10-15T00:30:00Z
- Category: company_news; sentiment: bullish; impact: medium
- Symbols: [TSE:4502](https://stocks.freetheai.org/symbols/TSE-4502)
- Written by our AI from expert market sources across the web for FreeTheAI Stocks, built by Vibhek Soni
- How write-ups are made: https://stocks.freetheai.org/how-we-write
- Not financial advice: https://stocks.freetheai.org/disclaimer

Takeda Pharmaceutical Company Limited (TSE:4502) has launched ORZEYFUL (oveporexton) in Japan and China. The simultaneous rollout gives physicians in both countries their first opportunity to prescribe the new treatment to patients diagnosed with narcolepsy type 1.

ORZEYFUL is a first-in-class OX2R agonist that targets the underlying mechanism of narcolepsy type 1 rather than addressing symptoms alone. In Phase 3 clinical trials, the therapy demonstrated broad symptom gains compared to placebo, along with a generally well-tolerated safety profile. The launch advances the company's orexin franchise into commercial distribution across two major Asian markets. Following the news, shares of Takeda rose 2.77% to 6,052 JPY.

Investors and market observers will be watching early prescription adoption by specialists, reimbursement developments in both regions, and potential future label expansions or regulatory submissions in the United States and Europe.

## Key points

- Takeda Pharmaceutical launched ORZEYFUL in Japan and China for narcolepsy type 1 patients.
- ORZEYFUL is a first-in-class OX2R agonist providing a new treatment mechanism for narcolepsy.
- Phase 3 study data showed broad symptom improvements over placebo with manageable safety.
- Shares of Takeda Pharmaceutical rose 2.77% to 6,052 JPY after the rollout announcement.

## Questions and answers

### What is ORZEYFUL and what condition does it treat?

ORZEYFUL (oveporexton) is a first-in-class OX2R agonist approved for the treatment of narcolepsy type 1.

### In which markets has Takeda launched ORZEYFUL?

Takeda Pharmaceutical has launched ORZEYFUL in Japan and China, marking physician access in both countries.

### How did Takeda stock react to the news?

Shares of Takeda Pharmaceutical Company Limited rose 2.77% to 6,052 JPY following the announcement.